source
- STAT+: Servier to buy Edgewise Therapeutics’ muscular dystrophy drugThe French pharma firm Servier is buying an experimental muscular dystrophy drug from Edgewise Therapeutics for $1.55 billion upfront.STAT · 2mo ago↗ source
- #ASCO26: AstraZeneca's triplet combo succeeds in liver cancer subgroupCHICAGO — AstraZeneca on Monday reported data from a new study showing the combination of a targeted treatment and two immunotherapies can benefit patients with certain kinds of liver cancer. Indiv…Endpoints · 2mo ago↗ source
- Lilly licenses GLP-2 asset from Korean biotech Hanmi for $75M upfrontEli Lilly, which has made billions off the success of its GLP-1 drugs, is now making a play for GLP-2s through a licensing deal with Hanmi. The Indianapolis drugmaker will pay $75 million upfront i…